Grace Wilson, MD
Pulmonary Disease · Columbia, MONPI 1750761532
Payments from drug & device makers
Across 184 payments — averaging $21.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$839
- GSK$379
- Sanofi$294
- Regeneron Healthcare Solutions, Inc.$223
- Grifols USA, LLC$216
- United Therapeutics Corporation$213
- plus $2K from 24 others
What the payments were for
- Food & beverage$4,032100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 37 | $839 |
| GSK | 18 | $379 |
| Sanofi | 9 | $294 |
| Regeneron Healthcare Solutions, Inc. | 9 | $223 |
| Grifols USA, LLC | 10 | $216 |
| United Therapeutics Corporation | 9 | $213 |
| Boehringer Ingelheim | 9 | $199 |
| Amgen | 11 | $196 |
| Genentech USA, Inc. | 7 | $166 |
| Bayer | 5 | $152 |
| Electromed, Inc. | 16 | $140 |
| Veran Medical Technologies, Inc. | 2 | $131 |
| Mylan Specialty L.p. | 6 | $116 |
| Actelion Pharmaceuticals US, Inc. | 2 | $103 |
| Insmed, Inc. | 4 | $93 |
| Mallinckrodt Hospital Products Inc. | 4 | $84 |
| Novartis | 4 | $68 |
| Baxter Healthcare | 3 | $67 |
| Pulmonx Corporation | 3 | $50 |
| Resmed Corp | 3 | $50 |
| Inspire Medical Systems, Inc. | 1 | $40 |
| Merck | 2 | $38 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $32 |
| Biomerieux Inc | 1 | $29 |
| Jazz Pharmaceuticals Inc. | 2 | $28 |
| Inogen, Inc. | 2 | $23 |
| Philips North America LLC | 1 | $21 |
| Viatris Specialty LLC | 1 | $17 |
| Paratek Pharmaceuticals, Inc. | 1 | $12 |
| Breas Medical, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,032 in reported general payments places this provider in the 55th percentile of 295 pulmonary disease providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 98 | $75,232 |
| Breo ElliptaFluticasone/Vilanterol | 53 | $29,712 |
| Advair HfaFluticasone Propion/Salmeterol | 57 | $25,269 |
| Spiriva HandihalerTiotropium Bromide | 28 | $19,974 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 23 | $17,273 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 25 | $17,271 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 24 | $12,422 |
| Spiriva RespimatTiotropium Bromide | 12 | $11,593 |
| SymbicortBudesonide/Formoterol Fumarate | 19 | $6,276 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 42 | $5,344 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 178 | $3,795 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 18 | $3,502 |
| Arnuity ElliptaFluticasone Furoate | 12 | $3,398 |
| Roflumilast | 39 | $1,675 |
| Montelukast Sodium | 68 | $726 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $379 | $120,764187 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat | $199 | $28,86437 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $839 | $23,54942 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 295 pulmonary disease providers in Missouri.
Other pulmonary disease in Columbia
- Aaron MillerColumbia$154K
- Jason GoodinColumbia$17K
- Steven HullLees Summit$10.1M
- Thomas SilerSaint Charles$5.5M
- Neil EttingerChesterfield$3.5M
- Humam FarahHannibal$2.7M
- Murali ChakinalaSaint Louis$2.4M
- Joseph OjileSaint Louis$2.1M
- Jeffrey HarrisSaint Louis$1.1M
- Kaharu SuminoSaint Louis$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.